Anti-emetic prophylaxis with oral tropisetron and/or dexamethasone

Department of Anaesthesiology and Intensive Care, University Hospital Giessen-Marburg, Marburg, Germany.
European Journal of Clinical Investigation (Impact Factor: 2.73). 09/2006; 36(8):580-7. DOI: 10.1111/j.1365-2362.2006.01671.x
Source: PubMed


The corticosteroid dexamethasone and the serotonine3 -antagonist tropisetron are both effective drugs for the prophylaxis of post-operative nausea and vomiting (PONV) when given intravenously. The aim of this trial was to evaluate the oral use of both drugs as part of a routine oral premedication and to compare their single and combined effectiveness.
In this randomized, placebo-controlled, double-blind study, 320 inpatients with a moderate-high risk of PONV (> or = 40% according to two validated risk scores) received an oral premedication 1-2 h pre-operatively with placebo, a fixed dose of tropisetron 5 mg, dexamethasone 8 mg, or a combination of both drugs. A standardized general anaesthesia was performed, including benzodiazepine premedication, propofol, rocuronium, desflurane in air/O2, fentanyl or sufentanil followed by a continuous infusion of remifentanil. Post-operative analgesia and anti-emetic rescue medication were standardized. The main outcome measures were the severity of PONV within the first 24 h (rated by a standardized scoring algorithm). The incidence of PONV was used as the secondary outcome.
Data from 310 patients were analyzed. The mean severity score in the placebo-, tropisetron-, dexamethasone- and the combined-groups was 1.37, 0.8, 0.8 and 0.38, respectively. The incidence of PONV of any severity was 59.2%, 37.5%, 40% and 22.8%, respectively. The reduction of the incidence and the severity of PONV were statistically significant with all three interventions. Results from additional analyses suggested that both drugs were equally effective and that there was a simple additive effect of tropisetron and dexamethasone compared with placebo.
Oral tropisetron and dexamethasone were both equally effective in reducing the severity and incidence of post-operative nausea and vomiting. The latter could be reduced by approximately 35% in a population of moderate-high risk for PONV. Both drugs had an additive effect. However, even in the combination group there still remained an unacceptably high incidence of PONV of more than 20%. This highlighted the need for a multimodal anti-emetic approach in high-risk patients and the importance of treatment of PONV.

4 Reads
    • "Our findings in this regard were similar to the observation of those of Raid and Eberhart[3233] Both of these studies were done on children aged between 4–12 years old who had a high incidence of PONV, following strabismus repair surgery and anesthesia were induced and maintained by sevoflurane. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nausea and vomiting are common postoperative complications with incidence of 20-80% depends on the surgery type, anesthetic drugs, age, sex, etc. This complication may lead to patient discomfort, intraocular, and intracerebral pressures increase, sutures rupture, esophageal injury, and rarely death. Many studies reported that midazolam and dexamethasone alone can decrease postoperative nausea and vomiting (PONV), but their combination has never been studied yet. The aim of this study was to compare the effect of midazolam and midazolam-dexamethasone on PONV after middle ear surgery. 66 ASA I and II patients aged 15-65 year scheduled for elective middle ear surgery under general anesthesia randomly divided into two groups. Immediately after induction of the anesthesia group one (M) received midazolam 0.075 mg/kg and group two (M+D) received combination of midazolam (0.075 mg/kg) plus dexamethasone (0.05 mg/kg). Then the severity of nausea was measured by visual analog scales 0-10 (VAS) in recovery room at 6, 12, and 24 h after surgery. Metoclopramid (0.1 mg/kg) was administrated I.V. slowly if nausea score was above 3 or patient had vomiting. The postoperative need for antiemetics and the duration of stay in recovery room were recorded. Values of P<0.05 were considered statistically significant. There were no significant differences in age, gender, and weight between the two groups. There was no significant difference in the mean nausea scores between two groups except after 12 h postoperatively (1.39 ± 3.19 in M group vs. 0.42 ± 1.71 in M+D group). The mean vomiting frequency was significantly less in midazolam-dexamethasone group in the recovery room (0.9 ± 0.29 vs. 0 ± 0) and at 6-12 h (1.09 ± 2.41 vs. 0.3 ± 0.8), and 12-24 h (0.42 ± 1.32 vs. 0.03 ± 0.17) postoperatively. During the first 24 h postoperatively, the metoclopramid consumption was significantly less in combination therapy (6.48 ± 9.54) than in the midazolam group (12.9 ± 23.44) (Value<0.5). The combination of midazolam-dexametazone is more effective than midazolam alone in prevention of postoperative vomiting after middle ear surgery. Therefore, we recommend combination therapy for patients who are prone to PONV.
    05/2012; 1:9. DOI:10.4103/2277-9175.96052
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: 5-HT3 receptor antagonists (e.g. tropisetron) combined with dexamethasone are effective for the acute phase of cisplatin (CIS)-induced emesis. This study determined the possible additive or synergistic antiemetic efficacy of Delta9-THC when combined with tropisetron or dexamethasone (DEX). Delta9-THC (0-10 mg/kg i.p.) was injected in combination with tropisetron (0-5 mg/kg i.p.) or dexamethasone (0-20 mg/kg i.p.) prior to CIS (20 mg/kg i.p.) in the least shrew, and the induced emesis was recorded for 60 min. CIS-induced vomiting was dose-dependently and significantly attenuated by individual administration of Delta9-THC (59-97% reductions) and tropisetron (79-100% attenuation), but not dexamethasone (26-40%), although a trend (p<0.1) towards reduced vomiting frequency following DEX was noted. Low doses of Delta9-THC (0.25 or 0.5 mg/kg) when combined with low doses of tropisetron (0.025, 0.1, or 0.25 mg/kg) were more efficacious in reducing emesis frequency than when given individually, but Delta9-THC had no antiemetic interactions with DEX. However, no tested combination provided a significantly greater effect on the number of animals vomiting than their individually-administered counterparts. The modest interaction of Delta9-THC with tropisetron suggests they activate overlapping antiemetic mechanisms, while the lack of interaction with dexamethasone needs further clarification.
    Pharmacology Biochemistry and Behavior 08/2008; 91(3):367-73. DOI:10.1016/j.pbb.2008.08.008 · 2.78 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This chapter discusses general anesthetics and therapeutic gases. The effect of intravenous fentanyl given before thiopental induction on airway irritation caused by a stepwise increase in desflurane was studied in 80 children aged 2–8 years in a double-blind, randomized, placebo-controlled study. Fentanyl reduced the incidence of airway irritation (cough 2.5% versus 43%; secretions 28% versus 83%; excitation 10% versus 83%; apnea 20% versus 65%). The mean expired desflurane concentration at which the first airway irritation symptom occurred was greater with fentanyl. In two studies the value of combining antiemetic agents in treating postoperative nausea and vomiting was demonstrated. Intravenous dexamethasone and tropisetron reduced the incidence of postoperative nausea and vomiting by about 35% in a double-blind, randomized, placebo-controlled study in 320 patients after anesthesia with benzodiazepine premedication, propofol, rocuronium, desflurane in air/O2, and fentanyl or sufentanil, followed by a continuous infusion of remifentanil. The two drugs had additive effects, although even in the combination group the incidence of nausea and vomiting was still unacceptably high.
    Side Effects of Drugs Annual 12/2009; 31:217-229. DOI:10.1016/S0378-6080(09)03110-9
Show more